key: cord-0274357-lbpyxa0b authors: Pavot, Vincent; Berry, Catherine; Kishko, Michael; Anosova, Natalie G.; Huang, Dean; Tibbitts, Tim; Raillard, Alice; Gautheron, Sylviane; Gutzeit, Cindy; Koutsoukos, Marguerite; Chicz, Roman; Lecouturier, Valerie title: SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primates date: 2021-09-21 journal: bioRxiv DOI: 10.1101/2021.09.20.461023 sha: 44009440fe5805a0d6eced80d5c68206d7eb17d9 doc_id: 274357 cord_uid: lbpyxa0b The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that partly evade neutralizing antibodies has raised concerns of reduced vaccine effectiveness and increased infection. We previously demonstrated in preclinical models and in human clinical trials that our SARS-CoV-2 recombinant spike protein vaccine adjuvanted with AS03 (CoV2 preS dTM-AS03) elicits robust neutralizing antibody responses in naïve subjects. Here, the objective was to document the potency of various booster vaccine formulations in macaques previously vaccinated with mRNA or protein subunit vaccine candidates. We show that one booster dose of AS03-adjuvanted CoV2 preS dTM, D614 (parental) or B.1.351 (Beta), in monovalent or bivalent (D614 + B.1.351) formulations, significantly boosted pre-existing neutralizing antibodies and elicited high and stable cross-neutralizing antibodies covering the four known SARS-CoV-2 variants of concern (Alpha, Beta, Gamma and Delta) and, unexpectedly, SARS-CoV-1, in primed macaques. Interestingly, the non-adjuvanted CoV2 preS dTM B.1.351 vaccine formulation also significantly boosted and broadened the neutralizing antibody responses. Our findings show that these vaccine candidates used as a booster have the potential to offer cross-protection against a broad spectrum of variants. This has important implications for vaccine control of SARS-CoV-2 variants of concern and informs on the benefit of a booster with our vaccine candidates currently under evaluation in phase 2 and 3 clinical trials (NCT04762680 and NCT04904549). Emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern 38 (VoC), Alpha in late 2020 and Delta in spring 2021, have sparked concerns about transmissibility 39 and pathogenicity 1, 2, 3 . These VoC harbor specific mutations in the spike protein impacting of waning immunity after natural infection or immunization and the risk of antibody escape by 51 emerging variants, the key attributes of future vaccines will be the ability to boost, prolong, and 52 broaden protective immunity against COVID-19 and new emerging variants. 53 Here we formulated soluble prefusion-stabilized spike trimers (CoV2 preS dTM) with the well 54 characterized adjuvant AS03, an oil-in-water emulsion composed of α-tocopherol, squalene and 55 polysorbate 80 12 . AS03 potently induces antibody responses and has been shown to increase 56 vaccine durability, promote heterologous strain cross-reactivity and to have dose-sparing effects 13, 57 14 . We previously reported that CoV2 preS dTM-AS03 (D614) confers protective efficacy against 58 SARS-CoV-2 (USA-WA1/2020 isolate) challenge in non-human primates and that vaccine-59 induced IgG mediated protection from SARS-CoV-2 challenge following passive transfer to hamsters 15 . We also showed safety and immunogenicity in humans in a phase 1/2 clinical trial 16 61 and, an optimized vaccine formulation is being assessed in a dose-ranging phase 2 clinical trial 62 (NCT04762680) and a phase 3 efficacy trial (NCT04904549). 63 In this work, the objective was to assess a subunit vaccine booster in macaques vaccinated 7 months One booster dose of CoV2 preS dTM boosts pre-existing neutralizing antibodies against 74 D614G with significant AS03-adjuvant effect. 75 Following primary vaccination with either mRNA-LNP or CoV2 preS dTM-AS03, we assessed 76 the neutralizing antibody (NAb) responses against the D614G. Using a GFP-based pseudovirus 77 NAb assay, the mean NAb titers at day 35 (D35; 2 weeks post-dose 2) against the D614G 78 pseudovirus were 2.6 log10 for the mRNA-primed cohort and 2.9 log10 for the subunit-primed 79 cohort (Fig. 1b) . Six months post-dose 2 (baseline pre-boost), mean D614G NAb titers declined to NAb titers compared to baseline as soon as 7 days after injection, reaching a plateau in 14 days in 89 both mRNA-primed (mean of 3.3 log10) and subunit-primed (mean of 3.5 log10) cohorts (p-90 values<0.001). As in each cohort, macaques were randomized for their baseline titers 6 months 91 post-primary vaccination and peak titers post-prime (D35), we analyzed the fold-increase of NAb 92 titers 14 days post-booster compared to baseline or post-prime. Mean increase in NAbs from 93 baseline were 60-fold (p-value<0.001) in mRNA-primed and 16-fold (p-value<0.001) in subunit-94 primed cohorts. Of note, baseline titers in the mRNA cohort were lower than in the subunit cohort. The mean D614G NAb titers 14 days post-booster were significantly higher than the peak titer post-priming vaccination at D35 (3. 2-fold, p-value<0.05 and 3.8-fold, p-value<0 .01 for mRNA-97 primed and subunit-primed cohorts respectively). A booster dose with adjuvanted CoV2 preS dTM-AS03 vaccine candidates (monovalent or bivalent 99 formulations) also significantly increased D614G NAb titers compared to baseline in both cohorts 100 as early as 7 days after injection and by 14 days the mean titers were 4.0 log10 in mRNA-primed 101 (mean fold-increase of 370 from baseline, p-values<0.001) and 4.4 log10 in subunit-primed (mean 102 fold-increase of 177 from baseline, p-values<0.001) animals. In both the mRNA-and subunit-primed cohorts, after the AS03-adjuvanted booster, the D614G NAb titers (at all timepoints post-boost) were significantly higher than the peak titers post-priming 105 vaccination at D35 (mean fold-increase of 21 in the mRNA-primed cohort and a mean fold-increase 106 of 31 in the subunit-primed cohort; p-values<0.001). There were no statistically significant 107 differences in D614G NAb titer increase (from D35 post-primary vaccination or from baseline pre-108 booster) between the various AS03-adjuvanted vaccine formulations. In both cohorts, a significant adjuvant effect was observed on the fold-increase from baseline The D614G NAb titers elicited by non-adjuvanted CoV2 preS dTM (B.1.351) booster were all 115 higher than the mean D614G NAb titers of human convalescent sera (2.2 Log10) , and all AS03-116 adjuvanted boost candidate vaccines induced titers above the highest titer observed in human 117 convalescent sera in the subunit-primed cohort (the lowest D614G NAb titers was 3.6 log10 after 118 the AS03-adjuvanted boost, and the highest D614G NAb titer in human convalescent sera was 3.3 119 log10). 122 neutralizing antibodies with significant AS03-adjuvant effect. 123 We next assessed NAb titers against the Beta variant PsV (B.1.351) using the lentivirus-based 124 neutralization assay. After the primary immunization regimen of D0 and D21, NAb titers against 125 Beta variant were low to undetectable in the mRNA-primed cohort (mean titer of 1.4 log10) and 126 low in the subunit-primed cohort (mean titer of 1.6 log10) at D35 (Fig. 1c) . Six months post-dose 2 127 (D205 and D196), B.1.351 NAb titers were undetectable in the mRNA-primed cohort (